United States · Platforms & data · Stocktwits

Eli Lilly’s Orforglipron Wins Big In China – Gains Edge Over Novo In Race For Potential $4.5B Market

Published by Stocktwits · United States 11 h ago

Eli Lilly’s Orforglipron Wins Big In China – Gains Edge Over Novo In Race For Potential $4.5B Market — Stocktwits

Detailed summary

Orforglipron, which is marketed as Foundayo, became the first weight-loss pill to receive approval in China, according to a Reuters report.

Read the full article on Stocktwits Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (stocktwits.com)

Also worth reading

Humacyte FY2029 Earnings Forecast Decreased by HC Wainwright

Victoria's Secret downgraded as turnaround story fully priced in—BofA Securities

The Motley Fool

History Says the Nasdaq Will Soar Once Again in 2027 After the Sell-Off. The Best Growth Stock to Buy Before That Happens

Oil prices jump after Trump says no Iran deal needed: 'We've got their Strait'

It’s not ‘Medicare for All,’ but ‘Medicare for More.’ What this could mean for workers over 50.

Turtlemint H1 FY27 slides: losses narrow 49% as revenue climbs 38%